Rabacfosadine Literature


Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses

C. F. Saba, K. R. Vickery, C. A. Clifford, K. E. Burgess, B. Phillips, D. M. Vail, Z. M. Wright, M. A. Morges, T. M. Fan, D. H. Thamm



Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma

D.H. Thamm , D.M. Vail, G.S. Post, T.M. Fan, B.S. Phillips, S. Axiak-Bechtel, R.S. Elmslie,
M.K. Klein, and D.A. Ruslander



GS-9219–a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma.

Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB.



Assessment of GS-9219 in a pet dog model of non-Hodgkin’s lymphoma.

Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB.



GS-9219/VDC-1101–a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Thamm DH, Vail DM, Kurzman ID, Babusis D, Ray AS, Sousa-Powers N, Tumas DB.



Use of 3′-deoxy-3′-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin’s lymphoma.

Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM.


Rabacfosadine was previously referred to as VDC-1101 and GS-9219